Quick Answer
Vir Biotechnology, Inc. reported Net Income Loss of -$437.99 million for the year ending 2025.
- Vir Biotechnology, Inc. showed an increase of +16.1% in Net Income Loss from 2024 to 2025.
- This data is from Vir Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$31.59 million | Q2 2018: -$24.45 million | Q3 2018: -$33.46 million | Q4 2018: -$26.39 million | Q1 2019: -$28.67 million | Q2 2019: -$33.93 million | Q3 2019: -$48.31 million | Q4 2019: -$63.77 million | Q1 2020: -$77.24 million | Q2 2020: -$31.17 million | Q3 2020: -$84.61 million | Q4 2020: -$105.65 million | Q1 2021: -$168.91 million | Q2 2021: $61.81 million | Q3 2021: $110.43 million | Q1 2022: $518.62 million | Q2 2022: -$76.49 million | Q3 2022: $175.31 million | Q1 2023: -$140.96 million | Q2 2023: -$194.78 million | Q3 2023: -$163.41 million | Q1 2024: -$65.28 million | Q2 2024: -$138.38 million | Q3 2024: -$213.72 million | Q1 2025: -$120.97 million | Q2 2025: -$110.96 million | Q3 2025: -$163.14 million.
- Over the full 9 years of available data (2017 to 2025), Vir Biotechnology, Inc.'s Net Income Loss has declined by 527.0%.
- Historical annual values: Fiscal year 2025: -$437.99 million | Fiscal year 2024: -$521.96 million | Fiscal year 2023: -$615.06 million | Fiscal year 2022: $515.84 million | Fiscal year 2021: $528.58 million | Fiscal year 2020: -$298.67 million | Fiscal year 2019: -$174.68 million | Fiscal year 2018: -$115.88 million | Fiscal year 2017: -$69.85 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: